ETON Stock Analysis: Eton Pharmaceuticals | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 1.438m USD | 12M Return: 172.8% | US29772L1089 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 30.8M
Qual. Beats: 1
Rev. Trend: 95.7%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 7.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Eton Pharmaceuticals is a U.S.-based rare disease pharmaceutical company headquartered in Deer Park, Illinois, and listed on NASDAQ under the ticker ETON. Founded in 2017, the company develops and commercializes treatments for conditions with limited therapeutic options, operating within the orphan drug segment of the pharmaceuticals industry, which benefits from regulatory incentives such as extended market exclusivity under the U.S. Orphan Drug Act.
The companys commercial portfolio spans eight marketed products targeting endocrine and metabolic disorders, including Increlex for severe primary IGF-1 deficiency, Alkindi Sprinkle and Khindivi for adrenal insufficiency, Galzin for Wilson disease, PKU Golike for phenylketonuria, and treatments for NAGS deficiency, homocystinuria, and tyrosinemia type 1. These products address small patient populations, a defining characteristic of the rare disease business model that supports premium pricing and sustained revenue from niche markets.
In addition to its marketed products, Eton is advancing a late-stage pipeline of candidates targeting additional rare endocrine and metabolic conditions, including ET-600 for diabetes insipidus, Amglidia for neonatal diabetes mellitus, ET-700 for Wilson disease, ET-800 for adrenal insufficiency, and the ZENEO hydrocortisone autoinjector for adrenal crisis. The company completed its IPO in November 2018 and is classified within the Health Care sector as a small-cap pharmaceutical issuer.
- Rare disease product portfolio drives revenue growth
- Pipeline candidates ET-600 and Amglidia advance toward commercialization
- Competition from generic and rare disease drug makers pressures pricing
- Reimbursement and regulatory approvals for late-stage products key catalysts
| Net Income: 12.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 0.70 > 1.0 |
| NWC/Revenue: 22.23% < 20% (prev 51.30%; Δ -29.07% < -1%) |
| CFO/TA 0.13 > 3% & CFO 15.1m > Net Income 12.7m |
| Net Debt (3.22m) to EBITDA (19.9m): 0.16 < 3 |
| Current Ratio: 1.52 > 1.5 & < 3 |
| Outstanding Shares: last quarter (32.8m) vs 12m ago 21.92% < -2% |
| Gross Margin: 57.87% > 18% (prev 59.41%; Δ -1.54% > 0.5%) |
| Asset Turnover: 97.11% > 50% (prev 57.22%; Δ 39.88% > 0%) |
| Interest Coverage Ratio: 3.55 > 6 (EBIT TTM 15.4m / Interest Expense TTM 4.34m) |
| A: 0.20 (Total Current Assets 68.6m - Total Current Liabilities 45.1m) / Total Assets 115.8m |
| B: -0.86 (Retained Earnings -99.4m / Total Assets 115.8m) |
| C: 0.14 (EBIT TTM 15.4m / Avg Total Assets 108.7m) |
| D: 0.67 (Book Value of Equity 46.6m / Total Liabilities 69.2m) |
| Altman-Z'' = 0.19 = B |
| DSRI: 0.95 (Receivables 24.9m/14.5m, Revenue 105.6m/58.2m) |
| GMI: 1.03 (GM 59.41% / 57.87%) |
| AQI: 1.22 (AQ_t 0.39 / AQ_t-1 0.32) |
| SGI: 1.81 (Revenue 105.6m / 58.2m) |
| TATA: -0.02 (NI 12.7m - CFO 15.1m) / TA 115.8m) |
| Beneish M = -2.33 (Cap -4..+1) = BBB |
As of October 21, 2026, the stock is trading at USD 50.19 with a total of 313,453 shares traded. Over the past week, the price has changed by -5.89%, over one month by -9.26%, over three months by +22.21% and over the past year by +172.77%.
Current recommended Stop Loss: 46.60 (which is 7.2% or 1.2 ATR below the current price).
Eton Pharmaceuticals has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy ETON.
- StrongBuy: 4
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 71.5 | 42.5% |
P/E Trailing = 125.775
P/E Forward = 23.9234
P/S = 13.6182
P/B = 34.139
Revenue TTM = 105.6m USD
EBIT TTM = 15.4m USD
EBITDA TTM = 19.9m USD
Long Term Debt = 19.1m USD (from longTermDebt, last quarter)
Short Term Debt = 8.82m USD (from shortTermDebt, last quarter)
Debt = 30.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 1.08m
Net Debt = 3.22m USD (calculated: Debt 30.1m - CCE 26.8m)
Enterprise Value = 1.44b USD (1.44b + Debt 30.1m - CCE 26.8m)
Interest Coverage Ratio = 3.55 (Ebit TTM 15.4m / Interest Expense TTM 4.34m)
EV/FCF = 97.83x (Enterprise Value 1.44b / FCF TTM 14.7m)
FCF Yield = 1.02% (FCF TTM 14.7m / Enterprise Value 1.44b)
FCF Margin = 13.95% (FCF TTM 14.7m / Revenue TTM 105.6m)
Net Margin = 12.02% (Net Income TTM 12.7m / Revenue TTM 105.6m)
Gross Margin = 57.87% ((Revenue TTM 105.6m - Cost of Revenue TTM 44.5m) / Revenue TTM)
Gross Margin QoQ = 67.61% (prev 60.72%)
Tobins Q-Ratio = 12.45 (Enterprise Value 1.44b / Total Assets 115.8m)
Interest Expense / Debt = 14.42% (Interest Expense 4.34m / Debt 30.1m)
Taxrate = 0.49% (63.0k / 12.8m)
NOPAT = 15.3m (EBIT 15.4m * (1 - 0.49%))
Current Ratio = 1.52 (Total Current Assets 68.6m / Total Current Liabilities 45.1m)
Debt / Equity = 0.65 (Debt 30.1m / totalStockholderEquity, last quarter 46.6m)
Debt / EBITDA = 0.16 (Net Debt 3.22m / EBITDA 19.9m)
Debt / FCF = 0.22 (Net Debt 3.22m / FCF TTM 14.7m)
Total Stockholder Equity = 31.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 11.67% (Net Income 12.7m / Total Assets 115.8m)
RoE = 40.13% (Net Income TTM 12.7m / Total Stockholder Equity 31.6m)
RoCE = 30.39% (EBIT 15.4m / Capital Employed (Equity 31.6m + L.T.Debt 19.1m))
RoIC = 20.65% (NOPAT 15.3m / Invested Capital 74.2m)
WACC = 6.00% (E(1.44b)/V(1.47b) * Re(5.83%) + D(30.1m)/V(1.47b) * Rd(14.42%) * (1-Tc(0.00)))
Discount Rate = 5.83% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 80.35 | Cagr: 11.31%
[DCF] Terminal Value 77.97% ; FCFF base≈13.7m ; Y1≈15.7m ; Y5≈23.2m
[DCF] Fair Price = 12.08 (EV 348.5m - Net Debt 3.22m = Equity 345.3m / Shares 28.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 4.0 | # QB: 1
Revenue Correlation: 95.67 | Revenue CAGR: 60.15% | SUE: 4.0 | # QB: 2
EPS current Quarter (2026-09-30): EPS=0.37 | Chg30d=+0.00% | Revisions=+25% | Analysts=2
EPS current Year (2026-12-31): EPS=1.40 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=+337.5% | GrowthRev=+87.3%
EPS next Year (2027-12-31): EPS=2.55 | Chg30d=-1.16% | Revisions=+25% | GrowthEPS=+82.1% | GrowthRev=+47.2%
[Analyst] Revisions Ratio: +50% (up=3, down=0)